Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Israel Agranat

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
Chemistry (Weinheim an Der Bergstrasse, Germany)|December 20, 2023
Comment on "Asymmetric Bistricyclic Aromatic Enes"Israel Agranat
Chirality|October 20, 2015
Classroom Enters the Courtroom: Stereochemistry of SN1 and SN2 Reactions in Enantiomer Patent Litigations of the Antidepressant EscitalopramElisheva Michman, Israel Agranat
Future Medicinal Chemistry|October 9, 2025
Consecutive double chiral-switches strategy. ADHD methylphenidate drugs: from two racemates via racemate to enantiomerIsrael Agranat, Ilaria D'Acquarica
ACS Medicinal Chemistry Letters|November 20, 2024
The Death of the Strategy of Classical Chiral Switches Is an ExaggerationIsrael Agranat, Ilaria D'Acquarica
The Journal of Organic Chemistry|November 21, 2007
Theoretical notions of aromaticity and antiaromaticity: phenalenyl ions versus fluorenyl ionsSergey Pogodin, Israel Agranat
ACS Medicinal Chemistry Letters|April 14, 2020
In Defense of Secondary Pharmaceutical Patents in Drug Discovery and DevelopmentIsrael Agranat, Hili Marom
Chirality|August 31, 2010
Racemization of the gastrointestinal antisecretory chiral drug esomeprazole magnesium via the pyramidal inversion mechanism: A theoretical studyHili Marom, Israel Agranat
Journal of the American Chemical Society|October 16, 2003
Biphenalenylidene: the forgotten bistricyclic aromatic ene. A theoretical studySergey Pogodin, Israel Agranat
The Journal of Organic Chemistry|January 5, 2002
Overcrowding motifs in large PAHs. An ab initio studySergey Pogodin, Israel Agranat
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|March 28, 2025
Racemic drugs are not necessarily less efficacious and less safe than their single-enantiomer componentsIsrael Agranat, Ilaria D'Acquarica
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
Chemistry (Weinheim an Der Bergstrasse, Germany)|December 20, 2023
Comment on "Asymmetric Bistricyclic Aromatic Enes"Israel Agranat
Chirality|October 20, 2015
Classroom Enters the Courtroom: Stereochemistry of SN1 and SN2 Reactions in Enantiomer Patent Litigations of the Antidepressant EscitalopramElisheva Michman, Israel Agranat
Future Medicinal Chemistry|October 9, 2025
Consecutive double chiral-switches strategy. ADHD methylphenidate drugs: from two racemates via racemate to enantiomerIsrael Agranat, Ilaria D'Acquarica
ACS Medicinal Chemistry Letters|November 20, 2024
The Death of the Strategy of Classical Chiral Switches Is an ExaggerationIsrael Agranat, Ilaria D'Acquarica
The Journal of Organic Chemistry|November 21, 2007
Theoretical notions of aromaticity and antiaromaticity: phenalenyl ions versus fluorenyl ionsSergey Pogodin, Israel Agranat
ACS Medicinal Chemistry Letters|April 14, 2020
In Defense of Secondary Pharmaceutical Patents in Drug Discovery and DevelopmentIsrael Agranat, Hili Marom
Chirality|August 31, 2010
Racemization of the gastrointestinal antisecretory chiral drug esomeprazole magnesium via the pyramidal inversion mechanism: A theoretical studyHili Marom, Israel Agranat
Journal of the American Chemical Society|October 16, 2003
Biphenalenylidene: the forgotten bistricyclic aromatic ene. A theoretical studySergey Pogodin, Israel Agranat
The Journal of Organic Chemistry|January 5, 2002
Overcrowding motifs in large PAHs. An ab initio studySergey Pogodin, Israel Agranat
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|March 28, 2025
Racemic drugs are not necessarily less efficacious and less safe than their single-enantiomer componentsIsrael Agranat, Ilaria D'Acquarica
Pageof 4